Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
Author(s):
Aluwini, S.; Pos, F.; Schimmel, E.; Krol, S.; Toorn, P.P. van der; Jager, H. de; Alemayehu, W.G.; Heemsbergen, W.; Heijmen, B.; Incrocci, L.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-04-30
Language
English
Is part of
The Lancet Oncology (2016), Vol. 17, no. 4, p. 464-474
